Protein Creatinine Ratio Calculator

The protein-to-creatinine ratio (PCR) is a widely used clinical test that estimates the amount of protein being lost in urine relative to creatinine concentration, allowing a 24-hour urinary protein excretion to be inferred from a single spot urine sample. Because both protein and creatinine are measured from the same sample, the ratio effectively corrects for urine dilution, making PCR far more convenient than timed urine collections while retaining good diagnostic accuracy. Protein in urine (proteinuria) is a hallmark of kidney disease. Healthy glomeruli are highly selective barriers that prevent large proteins like albumin from passing into the filtrate. When glomeruli are damaged — by diabetes, hypertension, autoimmune conditions such as lupus, or intrinsic glomerular disease — this selectivity breaks down and protein leaks into the urine. The amount of protein lost per day correlates with both the severity of kidney damage and the rate of disease progression. Detecting and quantifying proteinuria is therefore central to the diagnosis, staging, and monitoring of chronic kidney disease. Creatinine is a metabolic waste product of creatine phosphate in muscle, produced at a roughly constant rate proportional to muscle mass. Because daily creatinine excretion is relatively stable for a given individual, measuring urine creatinine alongside protein allows the protein concentration to be normalised for urine volume. This is the key insight behind PCR: a concentrated urine sample will have a high protein concentration by itself, but if the creatinine is also proportionally elevated, the ratio remains stable and reflects true protein excretion rates. The calculation is straightforward: PCR = urine protein (mg/dL) ÷ urine creatinine (mg/dL). The resulting dimensionless ratio approximates grams of protein excreted per gram of creatinine per day, which in practice approximates grams per day for most adults with average muscle mass. Interpretation varies slightly by guideline, but a PCR below 0.2 is generally considered normal; 0.2–1.0 indicates mild proteinuria; 1.0–3.5 indicates moderate proteinuria requiring close monitoring; and values above 3.5 represent the nephrotic range, where urgent nephrological evaluation is warranted. Clinically, PCR is used across a spectrum of conditions. In patients with diabetes, it is employed to detect early diabetic nephropathy when only microalbuminuria is present (albumin-to-creatinine ratio is preferred for this purpose but PCR is also used). In hypertensive patients, serial PCR measurements track the effectiveness of antihypertensive treatment in reducing proteinuria. In suspected glomerulonephritis or nephrotic syndrome, a high PCR guides the decision to proceed to kidney biopsy. In the monitoring of systemic lupus erythematosus, PCR correlates with disease activity and response to immunosuppression. Limitations of the test include variability related to muscle mass — elderly or malnourished patients excrete less creatinine, which can artificially elevate the PCR and overestimate protein excretion. Conversely, individuals with high muscle mass may underestimate true protein loss. First morning void samples are preferred because they are more concentrated and better reflect overnight protein excretion. Exercise, fever, orthostatic stress, and urinary tract infections can transiently elevate protein without indicating structural kidney disease. Results should therefore always be interpreted alongside clinical context and ideally confirmed with a repeat sample if unexpectedly elevated. Treatment of significant proteinuria depends on the underlying cause. Renin-angiotensin system blockade (ACE inhibitors or ARBs) reduces intraglomerular pressure and proteinuria regardless of aetiology, and forms the cornerstone of nephroprotective therapy. Blood pressure control, glycaemic management in diabetes, and disease-specific immunosuppression in inflammatory nephropathies are additional pillars. The target is to reduce PCR to the lowest achievable level, as each halving of proteinuria is associated with a meaningful reduction in the rate of progression to end-stage kidney disease.